Company news

Dyadic International, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Dyadic Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress

November 9, 2021

Dyadic Appoints Chief Business Officer to Executive Leadership Team

November 8, 2021

Dyadic Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

August 11, 2021

Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics

August 10, 2021

Dyadic to Report Second Quarter 2021 Financial Results

July 28, 2021

Dyadic Announces Technology Transfer and Licensing Agreement With South Africa’s Rubic Consortium Aiming to Develop and Commercialize Vaccines for Distribution Throughout the African Continent

July 26, 2021

Dyadic announces development of COVID-19 Vaccine in India

May 25, 2021

Dyadic Reports First Quarter 2021 Financial Results and Highlights Recent Company Progress

May 12, 2021

Dyadic to Report First Quarter 2021 Financial Results

April 28, 2021

Dyadic Reports 2020 Year End Results and Recent Company Progress

March 29, 2021

UPDATE -- Dyadic Advancing Proprietary Owned COVID-19 vaccine candidate, DYAI-100, Towards Human Clinical Trial

March 28, 2021

Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants

March 21, 2021

Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100

March 17, 2021

Dyadic to Report Fourth Quarter and Full Year 2020 Financial Results

March 15, 2021

Dyadic Enters Collaboration with TurtleTree Scientific to Develop Recombinant Protein Growth Factors

February 1, 2021

Dyadic International Appoints New Board Member

January 10, 2021

Dyadic Announces Third Quarter 2020 Financial Results and Highlights Recent Company Progress

November 11, 2020

Dyadic Announces Collaboration with Jiangsu Hengrui Medicine for Biologic Drug Development

September 16, 2020

Dyadic Announces Second Quarter 2020 Results and Highlights Recent Company Progress

August 12, 2020

Dyadic to Report Second Quarter 2020 Financial Results on Thursday, August 13, 2020

July 29, 2020

Dyadic International Announces Fully Funded Human Health R&D Collaboration with a Top Five Pharmaceutical Company

July 14, 2020

Dyadic Announces Two New Fully Funded Collaborations with Leading Global Animal Health Companies

July 7, 2020

Dyadic Joins Russell 2000(R) Index and Russell 3000(R) Index

June 28, 2020

Dyadic and Frederick National Laboratory to Develop Cell Lines for COVID-19 Vaccine Candidates Using Dyadic's C1 Gene Expression Platform

June 9, 2020

Dyadic Reports 2020 First Quarter Results and Recent Developments

May 13, 2020

Dyadic to Report First Quarter 2020 Financial Results on Thursday, May 14, 2020

April 29, 2020

Dyadic Reports 2019 Year End Results and Recent Developments

March 29, 2020

Dyadic Announces Nonexclusive Research License with WuXi Biologics

March 29, 2020

Dyadic Presents New Business Opportunities to Address COVID-19, Influenza and Continued Scientific and Business Development Progress

March 17, 2020

Dyadic to Report Year End 2019 Financial Results on Monday, March 30, 2020

March 15, 2020

Dyadic and The Israel Institute for Biological Research (IIBR) Expand Collaboration to Combat Emerging Diseases

February 24, 2020

Dyadic Announces New Milestone as G2 Human Like Glycosylation Reached

February 23, 2020

Dyadic Announces Achieving Human Like Glycan Structures From Its Engineered C1 Cell Line

November 24, 2019

Dyadic Reports Third Quarter 2019 Results And Recent Developments

November 12, 2019

Dyadic to Report Third Quarter 2019 Financial Results on Wednesday November 13, 2019

October 29, 2019

Dyadic Announces New Collaboration with Leading Animal Health Company

October 27, 2019

← Newer news releases

Calls

The 5 newest of 23 calls. Every call is listed under its year.

Decks

The 5 newest of 16 decks. Every deck is listed under its year.